Keros Deferred Long Term Liab from 2010 to 2025
| KROS Stock | USD 10.94 0.03 0.27% |
Deferred Long Term Liabilities | First Reported 2010-12-31 | Previous Quarter 360 K | Current Value 320 K | Quarterly Volatility 21.8 K |
Check Keros Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Keros Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 0.0 or Interest Income of 3.1 M, as well as many indicators such as Price To Sales Ratio of 7.3 K, Dividend Yield of 0.0 or PTB Ratio of 3.85. Keros financial statements analysis is a perfect complement when working with Keros Therapeutics Valuation or Volatility modules.
Keros | Deferred Long Term Liab |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.